Explore the vast range of titles available.

The artificial kidney, one of the greatest medical inventions in the 20th century, has saved innumerable lives with end stage renal disease. Designs of artificial kidney evolved dramatically in decades of development. A hollow-fibered membrane with well controlled blood and dialysate flow became the major design of the modern artificial kidney. Although they have been well established to prolong patients’ lives, the modern blood purification system is still imperfect. Patient’s quality of life, complications, and lack of metabolic functions are shortcomings of current blood purification treatment. The direction of future artificial kidneys is toward miniaturization, better biocompatibility, and providing metabolic functions. Studies and trials of silicon nanopore membranes, tissue engineering for renal cell bioreactors, and dialysate regeneration are all under development to overcome the shortcomings of current artificial kidneys. With all these advancements, wearable or implantable artificial kidneys will be achievable.

The development of dialysis by early pioneers such as Willem Kolff and Belding Scribner set in motion several dramatic changes in the epidemiology, economics and ethical frameworks for the treatment of kidney failure. However, despite a rapid expansion in the provision of dialysis — particularly haemodialysis and most notably in high-income countries (HICs) — the rate of true patient-centred innovation has slowed. Current trends are particularly concerning from a global perspective: current costs are not sustainable, even for HICs, and globally, most people who develop kidney failure forego treatment, resulting in millions of deaths every year. Thus, there is an urgent need to develop new approaches and dialysis modalities that are cost-effective, accessible and offer improved patient outcomes. Nephrology researchers are increasingly engaging with patients to determine their priorities for meaningful outcomes that should be used to measure progress. The overarching message from this engagement is that while patients value longevity, reducing symptom burden and achieving maximal functional and social rehabilitation are prioritized more highly. In response, patients, payors, regulators and health-care systems are increasingly demanding improved value, which can only come about through true patient-centred innovation that supports high-quality, high-value care. Substantial efforts are now underway to support requisite transformative changes. These efforts need to be catalysed, promoted and fostered through international collaboration and harmonization.Dialysis is a life-saving therapy; however, costs of dialysis are high, access is inequitable and outcomes are inadequate. This Review describes the current landscape of dialysis therapy from an epidemiological, economic, ethical and patient-centred framework, and describes initiatives that are aimed at stimulating innovations in the field to one that supports high-quality, high-value care.

Patients with end-stage renal disease (ESRD) have limited treatment options, primarily dialysis and kidney transplantation. While dialysis effectively removes urea, it remains costly and inconvenient, whereas transplantation is feasible for only a small subset of patients. These challenges underscore the urgent need for innovative blood purification technologies. Wearable artificial kidney (WAK) devices represent a significant advancement, yet efficient urea adsorption remains a critical challenge for their functionality and compact design. In this study, molecular dynamics (MD) simulations were conducted to investigate urea adsorption on nitrogen-doped (N-doped) and phosphorus-doped (P-doped) carbon nanotubes (CNTs). Key analyses—including energy evaluation, radius of gyration ( ), radial distribution function (RDF), root-mean-square deviation (RMSD), solvent accessible surface area (SASA) and hydrogen bond (H-bond) assessments—were performed to compare the adsorption capacities of these materials. The results indicate that CNTs with 15% nitrogen doping exhibit superior urea adsorption, attributed to enhanced H-bond formation, reduced , increased adsorption energy, and a higher RDF peak. These findings suggest that N-doped CNTs are highly efficient adsorbents for WAK devices, offering promising advancements in blood purification technologies.

After decades of slow progress, researchers are exploring better treatments for kidney failure — which kills more people than HIV or tuberculosis. After decades of slow progress, researchers are exploring better treatments for kidney failure — which kills more people than HIV or tuberculosis.

Dialysis almost immediately saved lives when it was invented in the first half of the twentieth century to treat kidney disease by safely accessing a patient's blood supply and filtering toxins normally removed by the kidneys. The World Health Organization estimates that, each year, around 1.2 million people worldwide die from kidney failure. The reality is that chronic kidney disease needs the kind of coordinated global effort, involving funders, researchers and patient groups, that some other conditions attract.

Background Hemodialysis mainly relies on the “artificial kidney,” which plays a very important role in temporarily or permanently substituting for the kidney to carry out the exchange of waste and discharge of water. Nevertheless, a previous study on the artificial kidney has paid little attention to the optimization of factors and levels for reducing the solidification of the artificial kidney during the hemodialysis procedure. Thus, this study proposes an integrated model that uses the Taguchi method, omega formula, and back-propagation network to determine the optimal factors and levels for addressing this issue. Methods First, we collected the recommendations of medical doctors and nursing staff through a small group discussion, and used the Taguchi method to analyze the key factors at different levels. Next, the omega formula was used to convert the analysis results from the Taguchi method to assess the defect rate. Finally, we utilized back-propagation network algorithms to predict the optimal factors and levels for artificial kidney solidification, in order to confirm that the key factors and levels identified can effectively improve the solidification rate of the artificial kidney and thereby enhance the effect of hemodialysis. Results The research finding proposes the following as the optimal factors and levels for artificial kidney solidification: the amount of anticoagulation should be set at 500 units, the velocity of blood flow at 300 ml/min, the dehydration volume at 2.5 kg, and the vascular access type as autologous blood vessels. We obtained 270 sets of data from the patients of End Stage Renal Disease (ESRD) under the setting of the optimal combination of the factors at different levels; the defect rate of artificial kidney solidification is 12.9%, which is better than the defect rate of 32% in the original experiment. Meanwhile, the patient characteristics for physiological status in BMI, serum calcium, hematocrit, ferritin, and transferrin saturation percentage are improved by this study. Conclusion This conclusion validates the ability of the proposed model in this study to improve the solidification rate of the artificial kidney, thereby confirming the model’s use as a standard operation procedure in the hemodialysis experiment. The ideas behind and the implications of the proposed model are further discussed in this study.

The most common treatment option worldwide for persons with kidney failure is in-centre haemodialysis; however, this treatment has remained largely unchanged over decades owing to a lack of true patient-centred technological innovation. The development of safe and effective wearable forms of dialysis has the potential to transform the lives of these patients.

A target Kt/V of > 1.4 and use of a high-flux dialyzer are recommended for patients on hemodialysis. However, there is little information on the relationship between the dialyzer surface area and mortality in these patients. In this nationwide cohort study, we aimed to clarify this relationship by analyzing data from the Japanese Society for Dialysis Therapy for 2010–2013. We enrolled 234,638 patients on hemodialysis who were divided according to quartile for dialyzer surface area into the S group (small, < 1.5 m 2 ), M group (medium, 1.5 m 2 ), L group (large, 1.6 to < 2.0 m 2 ), or XL group (extra-large, ≥ 2.0 m 2 ). We assessed the association of each group with 3-year mortality using Cox proportional hazards models and performed propensity score matching analysis. By the end of 2013, a total of 53,836 patients on dialysis (22.9%) had died. There was a significant decrease in mortality with larger dialyzer surface areas. The hazard ratio (95% confidence interval) was significantly higher in the S group (1.15 [1.12–1.19], P  < 0.0001) and significantly lower in the L group (0.89 [0.87–0.92] P  < 0.0001) and XL group (0.75 [0.72–0.78], P  < 0.0001) than in the M group as a reference after adjustment for all confounders. Findings were robust in several sensitivity analyses. Furthermore, the findings remained significant after propensity score matching. Hemodialysis using dialyzers, especially super high-flux dialyzers with a larger surface area might reduce mortality rates, and a surface area of ≥ 2.0 m 2 is superior, even with the same Kt/V.

Since 2005, three human clinical trials have been performed with the Wearable Artificial Kidney (WAK) and Wearable Ultrafiltration (WUF) device. The lack of an adequate vascular access (VA) has been pointed out as the main limitation to their implementation. Based on the current level of understanding, we will make the first conceptual proposal of an adequate VA suitable for the WAK and the WUF. All the literature related to WAK and WUF was reviewed. Based on eight main publications the VA major characteristics were defined: a mean blood flow of 100 mL/min; the capability to allow prolonged and frequent dialysis treatments, without interfering in activities of daily living (ADL); safe and convenient connection/disconnection systems; reduced risk of biofilm formation and coagulation; high biocompatibility. A research was done in order to answer to each necessary technological prerequisites. The use of a device similar to a CVC with a 5Fr lumen, seems to be the most feasible option. Totally subcutaneous port devices, like the LifeSite(R) or Dialock (R) systems can be a solution to allow WAK or WUF to operate continuously while patients carry out their ADL. Recently, macromolecules that reduce the risk of thrombosis and infection and are integrated into a CVC have been developed and have the capability of overcoming these major limitations. With an adequate VA, portable HD devices can be acceptable options to address several unmet clinical needs of HD patients.

A wearable artificial kidney (WAK) stands poised to offer dialysis treatment with maximal temporal and spatial flexibility for end-stage renal disease (ESRD) patients, while portability has not yet been achieved due to difficulties in portable purification. The ion concentration polarization (ICP), one of the nanoelectrokinetic phenomenon, has garnered substantial attention in the realm of portable purification applications, owing to its remarkable capacity for charge separation. In this work, scalable ICP dialyzer with 10,000-fold increase in throughput, was applied for peritoneal dialysate regeneration. First, the mechanism underpinning dialysate purification was corroborated based on micro-nanofluidics. Simultaneously, the electrochemical reactions utilized the complete decomposition of uncharged toxin (urea), achieving approximately 99% clearance, while the ICP phenomenon promoted the removal of positively charged toxin (creatinine), achieving approximately 30% clearance. Second, 3-D scalable ICP dialyzer was developed with a creation of micro-nanofluidic environment inside. Throughput scalability was demonstrated up to 1 mL/min with average approximately 30% toxins clearance. Ultimately, the 3-D ICP dialyzer was applied to assist peritoneal dialysis (PD) using a bilateral nephrectomy rat model. We demonstrated that regenerated dialysate successfully reduced in vivo toxicity, with average toxins removal ratio of approximately 30% per cycle. We believe that the integration of this scalable ICP dialyzer into the WAK holds tremendous potential for substantially enhancing the quality of life for individuals with ESRD. Graphical abstract